Results 31 to 40 of about 552,206 (313)
Experimental and Molecular Medicine, 2019 Cancer: How a plant metabolite analog suppresses tumor growth A synthetic analog of a chemical found in fruit suppresses tumor growth by targeting an RNA-binding protein (hnRNPA2B1) and preventing the production of a pro-cancer regulatory factor.
Nak-Kyun Soung +21 more
doaj +1 more source
Antioxidant as an anticancer: consideration [PDF]
DARU Journal of Pharmaceutical Sciences, 2012 Cancer is an important non infectious disease that can be seen around the world and this medical disorder become important public health threaten. The treatment of cancer is still not fully effective and the research for improvement of cancer therapy is still required. In the present day, many new approaches for cancer treatment can be seen and the use
Wiwanitkit, Viroj, Chaiyasit, Kamon
openaire +2 more sources
Cells, 2018 Most cytotoxic agents have limited efficacy for solid cancers. Cell-cycle phase analysis at the single-cell level in solid tumors has shown that the majority of cancer cells in tumors is not cycling and is therefore resistant to cytotoxic chemotherapy ...
Shuya Yano, Robert M. Hoffman
doaj +1 more source
Viruses as anticancer drugs [PDF]
Trends in Pharmacological Sciences, 2007 Oncolytic viruses are being developed as anticancer drugs. They propagate selectively in tumor tissue and destroy it without causing excessive damage to normal non-cancerous tissues. When used as drugs, they must meet stringent criteria for safety and efficacy and be amenable to pharmacological study in human subjects. Specificity for neoplastic tissue
Stephen J, Russell, Kah-Whye, Peng
openaire +2 more sources
ΔIK17: An Antigen Expressed on Human Lymphocytes
The International Journal of Biological Markers, 1996 Anti-ΔIK17 monoclonal antibody was produced by fusing SP2/0/Ag14 myeloma with spleen cells of BALB/c mice immunized with normal human thymocytes. AΔIK17 antibody recognizes a 44kD cell surface protein detected on human lymphocytes.
R. Sotiriadou +5 more
doaj +1 more source
A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo
Neoplasia: An International Journal for Oncology Research, 2007 Glufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic cancer.
W. Steve Ammons +4 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia.
Jinwoo Kim +11 more
wiley +1 more source
Isolated pancreatic metastasis from Merkel cell carcinoma: a case report
Journal of Rare DiseasesMerkel cell carcinoma (MCC) is a rare type of skin cancer. It is an aggressive neuroendocrine carcinoma with a high tendency for local recurrence, lymphatic and distant metastasis.
Maria Igoumenidi +6 more
doaj +1 more source
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
The development of an anti-cancer peptide M1-21 targeting transcription factor FOXM1
Cell & Bioscience, 2023 Background Transcription factor FOXM1 is a potential target for anti-cancer drug development. An interfering peptide M1-21, targeting FOXM1 and FOXM1-interacting proteins, is developed and its anti-cancer efficacy is evaluated.
Haojie Cheng +9 more
doaj +1 more source